Description: Arvinas Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Home Page: www.arvinas.com
ARVN Technical Analysis
5 Science Park
New Haven,
CT
06511
United States
Phone:
203 535 1456
Officers
| Name | Title |
|---|---|
| Dr. John G. Houston Ph.D. | CEO, Pres & Director |
| Mr. Sean A. Cassidy CPA, CPA, M.B.A. | CFO & Treasurer |
| Dr. Ian Taylor Ph.D. | Chief Scientific Officer |
| Dr. Ronald A. Peck | Chief Medical Officer |
| Mr. Jeff Boyle | VP of Investor Relations |
| Mr. Matthew Batters J.D. | Gen. Counsel & Corp. Sec. |
| Dr. Randy Teel Ph.D. | Sr. VP of Corp. & Bus. Devel. |
| Mr. Steve Weiss | Sr. VP & Chief HR Officer |
| Dr. John A. Grosso Ph.D. | Sr. VP of R&D Technical Operations |
| Ms. Angela M. Cacace Ph.D. | Sr. VP of Neuroscience & Platform Biology |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 17.6991 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.1294 |
| Price-to-Sales TTM: | 17.6396 |
| IPO Date: | 2018-09-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 280 |